High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Douglas E. Gladstone; Marc G. Golightly; Thomas H. Brannagan

doi:10.1016/j.jneuroim.2007.07.005

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Douglas E. Gladstone, Marc G. Golightly, Thomas H. Brannagan

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

Original language	English (US)
Pages (from-to)	121-126
Number of pages	6
Journal	Journal of Neuroimmunology
Volume	190
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2007.07.005
State	Published - Oct 2007
Externally published	Yes

Keywords

CD4RA+
CD4RO+
Chronic inflammatory demyelinating polyneuropathy
High dose cyclophosphamide
Multiple sclerosis

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2007.07.005

Cite this

@article{80bdb0dd556f41f5afdefebab35b9a6e,

title = "High dose cyclophosphamide preferentially targets na{\"i}ve T (CD45/CD4/RA+) cells in CIDP and MS patients",

abstract = "Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and na{\"i}ve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, na{\"i}ve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Na{\"i}ve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.",

keywords = "CD4RA+, CD4RO+, Chronic inflammatory demyelinating polyneuropathy, High dose cyclophosphamide, Multiple sclerosis",

author = "Gladstone, {Douglas E.} and Golightly, {Marc G.} and Brannagan, {Thomas H.}",

year = "2007",

month = oct,

doi = "10.1016/j.jneuroim.2007.07.005",

language = "English (US)",

volume = "190",

pages = "121--126",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

AU - Gladstone, Douglas E.

AU - Golightly, Marc G.

AU - Brannagan, Thomas H.

PY - 2007/10

Y1 - 2007/10

N2 - Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

AB - Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

KW - CD4RA+

KW - CD4RO+

KW - Chronic inflammatory demyelinating polyneuropathy

KW - High dose cyclophosphamide

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=35448938790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448938790&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.07.005

DO - 10.1016/j.jneuroim.2007.07.005

M3 - Article

C2 - 17854912

AN - SCOPUS:35448938790

SN - 0165-5728

VL - 190

SP - 121

EP - 126

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this